Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2602)	9/23/2009 3:09:48 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

OPXAW was up to $2 and it is still up 55.74% as it trades at the $1.90 level at present.<g> It said that it received $500,000 as a milestone payment from NVS under a stem cell technology transfer agreement. It also received about $850,000 from the exercise of outstanding warrants at a strike price of $1.78. Novartis agreed last month to acquire its pre-clinical stage stem cell technology, and received $3M upfront payment,with another $1M to be paid as a technology transfer fee over a 6 months period..<g> (The $500,000 is part of this $1M technology transfer fee.) OPXA traded at $2 earlier. Volume is over 430Ks. I don;t know its ADV.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2602)	10/13/2009 12:12:49 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

OPK is up 5.43% on volume of > 417,750 still below its ADV. The stock needs to close above its near resistance of $2.50 bigcharts.marketwatch.com It announced today that it has entered into a definitive agreement with Schering-Plough to acquire assets relating to Schering’s NK-1 receptor antagonist program. Rolapitant, the lead product, recently completed a PII for prevention of nausea and vomiting related to cancer chemotherapy and surgery. A PI has also been initiated for a second compound in the same class. It is anticipated that these compounds may have advantages over presently marketed products. In connection with its pending merger with MRK, SGP determined to divest its oral and intravenous formulations of rolapitant and other assets in its NK-1 program. Closing of the transaction between OPK and SGP is subject to completion of the merger. NK-1 receptors are highly concentrated in the brain and are also found in other tissues of the body. Activation of NK-1 receptors leads to the release of neurotransmitters and other signaling molecules that play a central role in controlling nausea and vomiting and other basic functions. Jamie Freedman, M.D., Ph.D., Executive Vice President of Research & Development at OPK commented: “The profile of rolapitant and the positive clinical data generated so far are very promising. We believe rolapitant has the potential to be a best-in-class product for preventing nausea and vomiting in the post-surgical setting or induced by cancer chemotherapy drugs. We will also be exploring various other uses of rolapitant.” The market for nausea and vomiting drugs is estimated to be in excess of $2B in the U.S., alone. NK-1 receptor antagonists and 5-HT3 receptor antagonists are major classes of drugs used for prevention of nausea and vomiting, and, while there are several approved 5HT-3 receptor antagonists, there is only one NK-1 receptor antagonist approved for commercial use, aprepitant (Emend). As mentioned, OPK seems to continue to put its recently raised cash to work at a fast clip.<g> There is no ACTAY, but I will place my target at $3.50 <g> bigcharts.marketwatch.com Bernard